Author

Elísabeth Pérez-Ruiz

Andalusian Centre for Nanomedicine and BiotechnologyORCID 0000-0001-7204-0800Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Assay:flow cytometry· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Antonio Rueda‐DomíngueziD· 1 shared Beatriz Martínez-GálveziD· 1 shared Isabel BarragániD· 1 shared Juan Luis OnievaiD· 1 shared Laura Cristina Figueroa-Ortiz· 1 shared Manuel Zalabardo-AguilariD· 1 shared Miguel‐Ángel Berciano‐GuerreroiD· 1 shared Vesa VilkkiiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

8 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Antonio Rueda‐DomínguezORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Integrating tumor and immune cell transcriptomics to predict immune checkpoint inhibitor primary resistance in metastatic cutaneous melanoma

Juan Luis Onieva, Elísabeth Pérez-Ruiz, Vesa Vilkki, Miguel‐Ángel Berciano‐Guerrero, Laura Cristina Figueroa-Ortiz, Manuel Zalabardo-Aguilar, Beatriz Martínez-Gálvez, Isabel Barragán, Antonio Rueda‐Domínguez

This study identifies an 82-gene transcriptomic signature predicting immune checkpoint inhibitor resistance in metastatic cutaneous melanoma using tumor and immune cell profiling.

bioRxiv · Aug 13, 2025 · PreprintCancer Biology